Today, we've recommended capivasertib (also called Truqap and made by AstraZeneca) with fulvestrant as an option for around 1,100 adults with hormone receptor (HR)-positive HER2-negative breast cancer ...

AKT inhibitor Truqap (capivasertib) has been cleared by NICE for use in combination with standard therapy fulvestrant for ...

New research targets two critical enzymes involved in the production of the hormone estrogen – aromatase and steroid ...

The trial evaluated the effectiveness of AstraZeneca’s camizestrant, an investigational next-generation oral selective ...

Optimal lead follicle size of 19 to 23 mm was associated with improved clinical pregnancy rates among patients undergoing IUI.

C, provided insights on what to consider when treating patients with HR+, HER2- breast cancer in the second line of treatment ...

In men, excess body fat increases aromatase activity, raising estrogen levels while ... When you carry too much weight, the ...

I am a baby boomer who was born in 1949. I was vaccinated against polio as soon as it was available, and I was most likely ...

Early initiation of moderate-intensity aerobic exercise during aromatase inhibitor use reduced pain and prevented pain increases among postmenopausal women with breast cancer. Early initiation of ...

Denosumab-bnht is expected to launch in the US in June 2025 per an agreement with the reference product’s manufacturer, Amgen.